310 related articles for article (PubMed ID: 29499974)
1. Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution.
Musso G; Gambino R; Cassader M; Paschetta E; Sircana A
Trends Pharmacol Sci; 2018 Apr; 39(4):387-401. PubMed ID: 29499974
[TBL] [Abstract][Full Text] [Related]
2. Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.
Wree A; Mehal WZ; Feldstein AE
Semin Liver Dis; 2016 Feb; 36(1):27-36. PubMed ID: 26870930
[TBL] [Abstract][Full Text] [Related]
3. Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment.
Liang C; Li J; Tian B; Tian L; Liu Y; Li J; Xin L; Wang J; Fu C; Shi Z; Xia J; Liang Y; Wang K
Biomed Pharmacother; 2021 Dec; 144():112298. PubMed ID: 34649219
[TBL] [Abstract][Full Text] [Related]
4. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.
Oniciu DC; Hashiguchi T; Shibazaki Y; Bisgaier CL
PLoS One; 2018; 13(5):e0194568. PubMed ID: 29847555
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic Steatohepatitis.
Suzuki A; Diehl AM
Annu Rev Med; 2017 Jan; 68():85-98. PubMed ID: 27732787
[TBL] [Abstract][Full Text] [Related]
6. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances.
Musso G; Saba F; Cassader M; Gambino R
Prog Lipid Res; 2023 Jul; 91():101238. PubMed ID: 37244504
[TBL] [Abstract][Full Text] [Related]
7. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).
Grattagliano I; Di Ciaula A; Baj J; Molina-Molina E; Shanmugam H; Garruti G; Wang DQ; Portincasa P
Methods Mol Biol; 2021; 2310():201-246. PubMed ID: 34096005
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
9. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
10. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
[TBL] [Abstract][Full Text] [Related]
11. Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model.
Machado MV; Kruger L; Jewell ML; Michelotti GA; Pereira Tde A; Xie G; Moylan CA; Diehl AM
Dig Dis Sci; 2016 Jan; 61(1):137-48. PubMed ID: 26403427
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
13. Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms.
Serhan CN
FASEB J; 2017 Apr; 31(4):1273-1288. PubMed ID: 28087575
[TBL] [Abstract][Full Text] [Related]
14. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis.
Dornas W; Lagente V
Pharmacol Res; 2019 Mar; 141():418-428. PubMed ID: 30658094
[TBL] [Abstract][Full Text] [Related]
15. In search of the magic bullet: can liver inflammation and fibrosis be reversed with medications?
Zimmermann HW; Tacke F
Expert Rev Gastroenterol Hepatol; 2015; 9(9):1139-41. PubMed ID: 26138749
[TBL] [Abstract][Full Text] [Related]
16. Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis.
Musso G; Cassader M; Paschetta E; Gambino R
Gastroenterology; 2018 Aug; 155(2):282-302.e8. PubMed ID: 29906416
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies.
Wattacheril J; Issa D; Sanyal A
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():649-662. PubMed ID: 29058997
[TBL] [Abstract][Full Text] [Related]
18. Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis.
Huang P; Kaluba B; Jiang XL; Chang S; Tang XF; Mao LF; Zhang ZP; Huang FZ
Biomed Res Int; 2018; 2018():8071093. PubMed ID: 29670908
[TBL] [Abstract][Full Text] [Related]
19. Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
Sundaram V; Morgan TR
Clin Liver Dis; 2019 Feb; 23(1):157-165. PubMed ID: 30454829
[TBL] [Abstract][Full Text] [Related]
20. Baicalin attenuates diet induced nonalcoholic steatohepatitis by inhibiting inflammation and oxidative stress via suppressing JNK signaling pathways.
Zhong X; Liu H
Biomed Pharmacother; 2018 Feb; 98():111-117. PubMed ID: 29247950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]